App-Quantinova.ai

DynAMo A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.

Paul Vincent Viscuse - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

CB-7598

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Jones T. Nauseef - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

taxane

Child Language Exposure and Early White Matter Plasticity: Interaction Speaks Louder Than Words

Sean Deoni - Pediatric Academic Societies (PAS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Pilot Trial of LENA HOME in a Home Visiting Program

John S. Hutton - Pediatric Academic Societies (PAS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept in the Treatment of Refractory Juvenile Dermatomyositis

Gulnara Mamyrova - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Juvenile dermatomyositis

Interferon

Efficiency of carbon nano tube (CNT) capture of blood circulating lung cancer cells

Rex Yung - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

The Anatomic Diagnosis of Venous Leak Using CT Cavernosography

Jack Campbell - New England Section of the American Urological Association (NEAUA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Male Sexual Dysfunction

N/A

Abnormal fractional anisotropy of the tremor network in tremor dominant Parkinson’s disease and Essential tremor plus syndrome

P. Pal - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Parkinson's disease

N/A

Abnormal streamline density of the tremor network in tremor dominant Parkinson’s disease and Essential tremor plus syndrome

S. Prasad - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Parkinson's disease

N/A

Circulating tumor cells (CTCs) as liquid biopsies in patients with metastatic colorectal cancer versus other GI malignancies.

Pashtoon Murtaza Kasi - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

ZoMaxx

Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.

Xiuli Yang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

anlotinib

Detection of DNA adduct γ-OHPdG in circulating tumor cells (CTCs) and its use as a prognostic biomarker in patients with hepatocellular carcinoma (HCC).

Aiwu Ruth He - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC).

Reetu Mukherji - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

N/A

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Rahul Raj Aggarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Pembrolizumab

Prognostic impact of circulating tumor cells in oligometastatic hormone-sensitive prostate cancer following metastasis-directed therapy.

Soha Bazyar - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Amy K Taylor - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

Enzalutamide

Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.

Santosh Gupta - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Prostate cancer

N/A

A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

Alan Haruo Bryce - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Umang Swami - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enfortumab vedotin

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

Charlotte Stahlfeld - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

IMMU132

Filters

1671 Abstracts